FDA’s latest oversight data reveal the scale of the compliance challenge: 29,178 medical device establishments registered with the agency in FY 2025, while FDA completed 3,732 inspections across registered drug and device sites. Therefore, medical device registration in 2026 requires much more than submitting company and product details. Manufacturers must correctly classify each device, build reliable technical and clinical evidence, maintain an effective quality system, and align FDA listing, EU MDR, CE marking, UDI, and EUDAMED records. This guide explains the complete process and shows how companies can reduce delays, compliance gaps, and global market-access risks.
Table of Contents
What Is Medical Device Registration in Regulatory Practice?
In regulatory practice, medical device registration means entering a manufacturer, authorized representative, or device into an authority’s official system before market access. However, registration differs from device listing, which records products linked to a registered establishment, and from a regulatory submission, which provides technical, clinical, and quality evidence for review. In the United States, FDA may grant 510(k) clearance, De Novo authorization, or PMA approval, depending on the device pathway. Meanwhile, under the EU MDR, a notified body may issue certification, while CE marking confirms that the manufacturer meets applicable requirements. Therefore, market authorization represents the broader legal right to place a device on a specific market after completing all required registration, assessment, and compliance steps.
Why Registration Controls Matter for GMP Compliance
Registration controls support GMP compliance because regulators expect manufacturers to connect every marketed device with a reliable quality system, clear risk controls, accurate labeling, and effective post-market surveillance. During the medical device registration process, companies must confirm that product information matches design records, manufacturing controls, intended use, and regulatory classifications. Moreover, teams must manage labeling changes, complaint data, vigilance reports, recalls, and corrective actions throughout the device lifecycle. Therefore, weak registration records can expose wider quality-system failures, delay market access, and increase the risk of inspection findings or enforcement action.
Four Controls That Determine Registration Readiness
A successful registration strategy depends on four connected controls that help manufacturers prove product safety, regulatory compliance, and lifecycle oversight. First, teams must confirm the device classification and intended use because these decisions shape every later requirement. Next, they must select the correct regulatory pathway and prepare the evidence that supports market authorization. In addition, manufacturers must align technical documentation, clinical evidence, labeling, traceability, and quality-system controls. Together, these elements reduce submission gaps, support inspection readiness, and prevent costly market-access delays.
The following four areas provide the foundation for effective registration readiness:
- Device Classification and Intended Use (PDF)
- Regulatory Pathway and Market Authorization (PDF)
- Technical Documentation and Clinical Evidence (PDF)
- Quality Systems, Labeling, and Traceability (PDF)
This infographic illustrates the key stages of medical device development, from initial concept and classification to technical documentation, clinical evidence, and registration-ready compliance.
Device Classification and Intended Use (PDF)
Manufacturers must define the device’s intended use before assigning its risk class because the intended purpose, patient population, duration of use, invasiveness, and mode of action shape classification. Therefore, an incorrect intended-use statement or classification can trigger the wrong conformity assessment route and delay market access.
Download EU MDR Device Classification and Intended Purpose Guide Here
Regulatory Pathway and Market Authorization (PDF)
Regulators use device classification, product novelty, supporting evidence, and market history to determine the appropriate pathway to market authorization. Therefore, manufacturers should compare FDA routes such as 510(k), De Novo, and PMA with EU conformity assessment and global reliance pathways before developing their registration strategy.
Download WHO Global Medical Device Regulatory Pathway and Market Authorization Framework Here
Technical Documentation and Clinical Evidence (PDF)
Manufacturers must connect device specifications, design records, risk controls, verification results, labeling, manufacturing information, and clinical evidence within one controlled technical documentation system. Moreover, they should update this evidence throughout the device lifecycle to support regulatory review, conformity assessment, and continued market compliance.
Download STED Guide to Medical Device Technical Documentation and Clinical Evidence Here
Quality Systems, Labeling, and Traceability (PDF)
Manufacturers must maintain a risk-based quality management system that controls design, production, documentation, labeling, complaints, and product changes throughout the device lifecycle. Moreover, accurate labels, batch or serial numbers, and unique device identification data help companies trace affected devices, investigate adverse events, and manage corrective actions or recalls.
Download EU MDR Guide to Medical Device Quality Systems, Labeling, and UDI Traceability Here
FDA Registration and Listing: What Inspectors Verify
FDA inspectors verify whether a manufacturer’s registration records accurately match its devices, regulatory activities, and quality-system documentation. First, companies must classify each device, select the correct product code, and complete any required 510(k), De Novo, or PMA pathway. Next, they must register the establishment and list each marketed device through FDA’s FURLS and Device Registration and Listing Module. Moreover, manufacturers must keep facility details, proprietary names, listing numbers, U.S. agent information, and premarket submission data accurate and consistent. Finally, they must review and verify their registration and listing information every year between October 1 and December 31, even when no information has changed. However, FDA registration and listing do not represent device clearance or approval.
This infographic presents the key FDA medical device registration steps, from device classification and regulatory pathway selection to establishment registration, device listing, and annual compliance verification.
EU MDR and EUDAMED: What Must Remain Consistent
EU market access requires manufacturers to align device classification, conformity assessment, CE marking, UDI, and EUDAMED records. Moreover, technical documentation, labeling, certificates, and registration data must remain consistent throughout the device lifecycle.
The following table summarizes the main steps from classification to EU market access.
| Key Documents and Records | Required Action | EU MDR Registration Stage |
|---|---|---|
|
Classification and Intended Purpose |
Define the intended purpose and assign Class I, IIa, IIb, or III. |
Intended purpose, classification rationale, labeling, EMDN code, and risk file |
|
Technical and Clinical Documentation |
Prepare design, risk, performance, validation, and clinical evidence. |
Technical file, clinical evaluation, GSPR checklist, labeling, and risk-management records |
|
Conformity Assessment |
Select the correct route and involve a Notified Body when required. |
Device class, QMS scope, technical documentation, audit records, and certificates |
|
CE Marking and UDI Assignment |
Issue the Declaration of Conformity, apply the CE mark, and assign UDI identifiers. |
Declaration, certificate, label, Basic UDI-DI, UDI-DI, and packaging data |
|
EUDAMED Registration and Maintenance |
Register economic operators and devices and update records throughout the lifecycle. |
SRN, EUDAMED entry, UDI data, certificates, labeling, PMS records, and vigilance reports |
This infographic shows how manufacturers move from medical device classification to EU medical device registration through technical documentation, clinical evaluation, conformity assessment, CE marking, UDI assignment, and EUDAMED device registration.
Final Words
A January 2026 FDA warning letter documented more than 41,000 device complaints that one manufacturer closed without investigation. This finding shows why medical device registration cannot remain a one-time administrative task. Manufacturers must keep classifications, listings, labels, UDI data, technical files, CAPA records, and post-market evidence aligned after market entry. Therefore, companies that manage registration as a lifecycle control can respond faster to inspections, protect patients, and reduce enforcement and market-access risks.
Medical Devices & IVDs EU Registration
We guide companies through medical device and IVD EU registration by supporting MDR and IVDR requirements, technical documentation, and structured processes for compliant market access.
FAQ
FDA inspectors compare establishment registration, device listings, product codes, premarket submission numbers, labeling, UDI data, complaint files, and quality-system records. GxP-regulated manufacturers must keep these records accurate and consistent across regulatory and operational systems.
Yes. Incorrect classification can trigger the wrong FDA submission or EU MDR conformity assessment route. It may also create gaps in clinical evidence, labeling, technical documentation, and post-market controls.
Yes. Manufacturers must assess changes to intended use, design, labeling, manufacturing sites, certificates, and authorized representatives. Significant changes may require an updated listing, EUDAMED record, regulatory submission, or new conformity assessment.
References
Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.